Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) reported a regulatory filing that coincided with a premarket uptick in its shares, which rose 5.6% on Tuesday morning after the company announced submission of an Investigational New Drug - IND - application to the U.S. Food and Drug Administration for QRX003. The application seeks authorization to evaluate QRX003 as a therapy for Peeling Skin Syndrome, a rare dermatologic condition for which no approved treatment or cure currently exists.
The company described the filing as the first IND ever submitted specifically for Peeling Skin Syndrome. Subject to the FDA's review and clearance, Quoin intends to begin a Phase 2 clinical trial during the second half of 2026.
Quoin said the IND submission is reinforced by clinical observations from an ongoing investigator-led pediatric study of PSS. According to the company, the initial participant in that study has received QRX003 for more than 15 months and has shown clinical improvements in skin condition, sleep patterns and overall quality of life. Quoin also reported that QRX003 has been well tolerated in that subject, with no adverse events recorded.
The planned Phase 2 study is expected to enroll between 6 and 8 pediatric and adult patients diagnosed with Peeling Skin Syndrome, with sites anticipated in both the United States and Europe. Quoin noted that this effort represents a second therapeutic indication for QRX003, adding to its development program in Netherton Syndrome.
In comments released by the company, Dr. Michael Myers, chief executive officer, characterized the IND submission as an additional milestone for Quoin and pointed out that the company was the first to submit an IND for Netherton Syndrome.
Quoin is advancing a separate program as well: QRX009, a topical rapamycin platform. The company indicated that QRX009 is targeted to enter clinical testing in the second half of this year.
Context and market reaction
The announcement tied to the IND filing produced a modest positive move in Quoin's trading ahead of the market open. The regulatory step and the planned Phase 2 trial extend the company's clinical pipeline by adding an investigational program for a rare dermatological disorder.
Limitations and available data
Quoin's submission relies on observations from an investigator-led pediatric study with a single described subject treated for over 15 months. The company reports improvements and tolerability in that subject, but broader safety and efficacy data across a larger cohort remain to be generated if the Phase 2 trial proceeds.